X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (12) 12
chemotherapy (11) 11
female (11) 11
male (11) 11
middle aged (11) 11
oncology (11) 11
aged (10) 10
hematology, oncology and palliative medicine (10) 10
cancer (9) 9
carcinoma, non-small-cell lung - drug therapy (9) 9
gefitinib (9) 9
lung cancer, non-small cell (9) 9
lung neoplasms - drug therapy (9) 9
adult (8) 8
mutation (8) 8
antimitotic agents (7) 7
antineoplastic agents (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
disease-free survival (7) 7
lung cancer (7) 7
lung neoplasms - pathology (7) 7
quinazolines - therapeutic use (7) 7
aged, 80 and over (6) 6
care and treatment (6) 6
erlotinib (6) 6
lung neoplasms - genetics (6) 6
medical colleges (6) 6
carcinoma, non-small-cell lung - genetics (5) 5
double-blind method (5) 5
lung neoplasms - mortality (5) 5
receptor, epidermal growth factor - genetics (5) 5
tumors (5) 5
antineoplastic agents - therapeutic use (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
clinical trials (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
egfr (4) 4
growth-factor receptor (4) 4
iii trial (4) 4
metastasis (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
protein kinase inhibitors - therapeutic use (4) 4
quinazolines - administration & dosage (4) 4
research (4) 4
survival analysis (4) 4
treatment outcome (4) 4
1st-line treatment (3) 3
adenocarcinoma (3) 3
cancer therapies (3) 3
carboplatin-paclitaxel (3) 3
cisplatin - administration & dosage (3) 3
drug administration schedule (3) 3
erlotinib hydrochloride (3) 3
kaplan-meier estimate (3) 3
multicenter (3) 3
open-label (3) 3
ovarian cancer (3) 3
paclitaxel (3) 3
product development (3) 3
proportional hazards models (3) 3
quinazolines - adverse effects (3) 3
receptor, epidermal growth factor - antagonists & inhibitors (3) 3
tyrosine kinase inhibitors (3) 3
acquired-resistance (2) 2
adenocarcinoma - drug therapy (2) 2
administration, oral (2) 2
analysis (2) 2
bevacizumab (2) 2
cancer patients (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - metabolism (2) 2
carcinoma, non-small-cell lung - secondary (2) 2
cell biology (2) 2
clinical-trials (2) 2
docetaxel (2) 2
drug therapy (2) 2
functional assessment (2) 2
gemcitabine (2) 2
genes, erbb-1 - genetics (2) 2
intention to treat analysis (2) 2
lung neoplasms - secondary (2) 2
patients (2) 2
protein kinase inhibitors - administration & dosage (2) 2
quality-of-life (2) 2
supportive care (2) 2
therapy (2) 2
time factors (2) 2
trial (2) 2
tyrosine (2) 2
1st-line chemotherapy (1) 1
abridged index medicus (1) 1
activation (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - mortality (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 735 - 742
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 213 - 222
Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | MULTICENTER | SOLID TUMORS | ONCOLOGY | ADENOCARCINOMA | CLINICAL-TRIALS | INHIBITOR | ERBB FAMILY BLOCKER | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Thailand - epidemiology | Asian Continental Ancestry Group - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Time Factors | Female | Odds Ratio | Republic of Korea - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - ethnology | Linear Models | Logistic Models | Treatment Outcome | China - epidemiology | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Intention to Treat Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Product development | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 619 - 626
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 953 - 961
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 466 - 475
Journal Article
11.